Long-term inhibition of dipeptidyl peptidase IV improves glucose tolerance and preserves islet function in mice

European Journal of Endocrinology

Volumn 146, Issue 5, 2002, Pages 717-727

  Reimer, M Kvist ^a   Holst, J J ^a   Ahren B ^a  

^a LUND UNIVERSITY   (Sweden)

Author keywords

[No Author keywords available]

Indexed keywords

6 [[2 [[2 (2 CYANO 1 PYRROLIDINYL) 2 OXOETHYL]AMINO]ETHYL]AMINO]NICOTINONITRILE; DIPEPTIDYL PEPTIDASE IV; DRINKING WATER; ENZYME INHIBITOR; FAT; GLUCAGON; GLUCAGON LIKE PEPTIDE 1; GLUCOSE; GLUCOSE TRANSPORTER 2; INSULIN; ISOPROTEIN; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL FOOD; ANIMAL MODEL; AREA UNDER THE CURVE; ARTICLE; BODY WEIGHT; CELL ISOLATION; CELL SIZE; CONTROLLED STUDY; DRUG ACTIVITY; DRUG SELECTIVITY; ENZYME ACTIVITY; ENZYME BLOOD LEVEL; ENZYME INHIBITION; FEMALE; GLUCOSE BLOOD LEVEL; GLUCOSE INTOLERANCE; GLUCOSE TOLERANCE; IMMUNOCYTOCHEMISTRY; IMMUNOREACTIVITY; INSULIN BLOOD LEVEL; INSULIN RELEASE; INSULIN RESISTANCE; LIPID DIET; MOUSE; MOUSE STRAIN; NONHUMAN; PANCREAS ISLET CELL FUNCTION; PRIORITY JOURNAL; PROTEIN EXPRESSION;

EID: 0036107064     PISSN: 08044643     EISSN: None     Source Type: Journal    
DOI: 10.1530/eje.0.1460717     Document Type: Article

References (49)

1. The incretin concept today
2. Cell and molecular biology of the incretin hormones glucagon-like peptide-I and glucose-dependent insulin releasing polypeptide
3. Glucagon-like peptide 1 (GLP-1) - A gut hormone of potential interest in the treatment of diabetes
4. Glucagon-like peptide 1 has a physiological role in the control of postprandial glucose in humans: Studies with the antagonist exendin 9-39
5. Effect of GIP and GLP-1 antagonists on insulin release in the rat
6. Glucose intolerance but normal satiety in mice with a null mutation in the glucagon-like peptide 1 receptor gene
7. Glucose intolerance caused by a defect in the entero-insulinar axis: A study in gastric inhibitory polypeptide receptor knockout mice
8. Inhibition of the activity of dipeptidyl-peptidase IV as a treatment for type II diabetes mellitus
9. Dipeptidyl-peptidase IV (CD26) - Role in the inactivation of regulatory peptides
10. Degradation of glucose-dependent insulinotropic polypeptide and truncated glucagon-like peptide 1 in vitro and in vivo by dipeptidyl peptidase IV
11. Degradation of glucagon-like peptide-1 by human plasma in vitro yields an N-terminally truncated peptide that is a major endogenous metabolism in vivo
12. Dipeptidyl peptidase IV inhibition reduces the degradation and clearance of GIP and potentiates its insulinotropic and antihyperglycemic effects in anesthetized pigs
13. Glucagon-like peptide-1-(7-36) amide is transformed to glucagon-like peptide-1-(9-36)amide by dipeptidyl peptidase IV in the capillaries supplying the L cells of the porcine intestine
14. Degradation of endogenous and exogenous gastric inhibitory polypeptide in healthy and in type 2 diabetic subjects as revealed using a new assay for the intact peptide
15. Dipeptidyl peptidase IV inhibition potentiates the insulinotropic effect of glucagon-like peptide 1 in the anesthetized pig
16. Inhibition of dipeptidyl peptidase IV with NVP-DPP728 increases plasma GLP-1 (7-36amide) concentrations and improves oral glucose tolerance in obese Zucker rats
17. Improved glucose tolerance and insulin secretion by inhibition of dipeptidyl peptidase IV in mice
18. Enhanced insulin secretion and improved glucose tolerance in mice lacking CD26
19. Improved glucose tolerance via enhanced glucose-dependent insulin secretion in dipeptidyl peptidase IV-deficient Fischer rats
20. Improved glucose tolerance in Zucker fatty rats by oral administration of the dipeptidylpeptidase IV inhibitor isoleucine thiazolidide
21. Inhibition of DPPIV by NVP DPP728 improves metabolic control over a 4 week period in type 2 diabetes
22. Insulinotropic hormone glucagon-like peptide-1(7-37) stimulation of proinsulin gene expression and proinsulin biosynthesis in insulinoma beta TC-1 cells
23. Glucagon-like peptide I stimulates insulin gene expression and increases cyclic AMP levels in a rat islet cell line
24. Glucagon-like peptide 1 induces differentiation of islet duodenal homeobox-1-positive pancreatic ductal cells into insulin-secreting cells
25. Dissociated insulinotropic sensitivity to glucose and carbachol in high-fat diet-induced insulin resistance in C57BL/6J mice
26. Potentiated β-cell response to non-glucose stimuli in insulin resistant C57BL/6J mice
27. Characterisation of beta-cell dysfunction of impaired glucose tolerance: Evidence for impairment of incretin-induced insulin secretion
28. Preserved incretin activity of glucagon-like peptide 1 [7-36amide] but not of synthetic human gastric inhibitory polypeptide in patients with type-2 diabetes mellitus
29. NVP-DPP728. (1-[[[2-[(5-cyanopyridin-2-yl)amino]ethyl]amino] acetyl]-2-cyano-(S)-pyrrolidine), a slow-binding inhibitor of dipeptidyl peptidase IV
30. Involvement of dipeptidyl peptidase IV in an in vivo immuno response
31. Potential therapeutic level of glucagon-like peptide-1 achieved in humans by a buccal tablet
32. Human colon produces fully processed glucagon-like peptide-1 (7-36)amide
33. Proglucagon products in plasma of noninsulin-dependent diabetics and nondiabetic controls in the fasting state and after oral glucose and intravenous arginine
34. Cloning and functional expression in bacteria of a novel glucose transporter present in liver, intestine, kidney, and β-pancreatic islet cells
35. Influence of glucagon-like peptide-1 on beta cell responsiveness
36. On the track to the beta-cell
37. Glucose uptake, utilization, and signaling in GLUT2-null islets
38. Diabetic hyperglycemia: Link to impaired glucose transport in pancreatic β-cells
39. NN2211, a long-acting GLP-1 derivative, ameliorates glycemia and reduces triglyceride levels in pre-diabetic ZDF rats in the absence of increased β-cell mass
40. Glucagon-like peptide-1 increases insulin sensitivity in depanreatized dogs
41. Glucose-lowering and insulin sensitizing actions of exendin-4: Studies in obese diabetic (b/ob, db/db) mice, diabetic fatty Zucker rats, and diabetic rhesus monkeys (Macaca mulatta)
42. GLP-1 does not acutely affect insulin sensitivity in healthy man
43. Effects of glucagon-like peptide-1 on islet function and insulin sensitivity in noninsulin-dependent diabetes mellitus
44. Dose-related effects of GLP-1 on insulin secretion, insulin sensitivity, and glucose effectiveness in mice
45. Contribution to glucose intolerance of insulin-independent vs insulin-dependent mechanisms in mice
46. Distribution of glucagon-like peptide I (GLP I), glucagon and glicentin in the rat brain: An immunocytochemical study
47. Enteroglucagon
48. Gene expression of the rat glucagon-like peptide-1 (GLP-1) receptor in rat brain
49. Central administration of GLP-1(7-36) amide inhibits food and water intake in rats